Final safety and efficacy results from a 106 real-world patients registry with an ascites-mobilizing pump.

ABSTRACT:

Background and aims

Patients with cirrhotic refractory ascites ineligible for transjugular intrahepatic shunt (TIPSS) have limited treatment options apart from repeated large volume paracentesis. The alfapump® is an implantable device mobilizing ascites from the peritoneal cavity to the bladder, from where it can be excreted. The aim of this observational cohort study was to prospectively investigate safety and efficacy of the device in a real-world cohort with cirrhotic refractory ascites and contraindications for TIPSS.

Methods

A total of 106 patients received an implant at 12 European centres and were followed up for up to 24 months. Complications, device deficiencies, frequency of paracentesis, clinical status and survival were recorded prospectively.

Results

Appr

SUBMITTER: Stirnimann G 

PROVIDER: S-EPMC9543940 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature